LGH IRB 2022-27: Phase 2 Study of ZNc3 in High-Grade Serous Ovarian Cancer
Enrolling By Invitation
99 years and younger
All
Phase
N/A
5 participants needed
1 Location
Brief description of study
This study will evaluate safety, clinical activity, and PK of ZN-c3 in subjects with platinum-resistant, high grade, serous ovarian, fallopian tube, or primary peritoneal cancer. Part 1a locally advanced/metastatic solid tumors with mutations in MRN complex genes or CCNE1 gene amplification. Part 1b primary peritoneal cancer. Part 2: PROC allocated to 1 of 3 cohorts based on CCNE1 gene amplification and cyclin E1 IHC. The drug is provided in the form of 25- or 100-mg tablets to be taken orally.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
22 Oct 2024.
Study ID: 856159
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
